Review on Experimental Research of Herbal Medicines with Anti-Amnesic Activity

Authors
Ming Tsuen Hsieh1, Wen Huang Peng1, Chi Rei Wu1, Kit Ying Ng1, Chuen Lung Cheng2, Hong Xi Xu2

Affiliations
1 Graduate Institute of Chinese Pharmaceutical Sciences, College of Pharmacy, China Medical University, Taichung, Taiwan
2 Hong Kong Jockey Club Institute of Chinese Medicine, Hong Kong, People’s Republic of China

Key words
amnesia
herbal medicines
cholinergic system
GABAergic system
glutaminergic system
memory enhancement

Abstract
Amnesia is characterized by the inability to form memories or total or partial loss of memory secondary to cerebral malfunction following degenerative diseases, cerebral infections, traumatic injuries and emotional events which could be differentiated from dementia. However, no effective treatment for amnesia is currently available. Much research effort has been focused on developing new drugs from herbal medicines which have multifunctional properties. Novel plant extracts and their major or bioactive components including alkaloids, flavonoids, glycosides and saponins with promising antioxidant effects, various effects on cholinergic, GABAergic, serotonergic, catecholaminergic and histaminergic systems, enhancement of cerebral blood flow and elevation of ribonucleic acid (RNA) as well as protein levels have been studied. In this review, we discuss the research findings on novel plant extracts and their bioactives with anti-amnesic effects on different neurotransmitter systems. Developing new drugs from herbal medicines for the treatment of amnesia is a hopeful attempt to meet the unmet medical needs.

Abbreviations
5,7-DHT: 5,7-dihydroxytryptamine
5-HT: serotonin
6-OHDA: 6-hydroxydopamine
Ach: acetylcholine
AChE: acetylcholinesterase
AD: Alzheimer’s disease
AGR: Acori graminei Soland., Araceae rhizome
AMPA: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
BBB: blood-brain barrier
BDPH: n-butylidenephthalide
cDNA: complimentary deoxyribonucleic acid
ChAT: choline-acetyltransferase
CNS: central nervous system
E-p-MCA: E-p-methoxycinnamic acid
FDA: Food and Drug Administration
GABA: gamma-aminobutyric acid
GBE: Ginkgo biloba L., Ginkgoaceae extract
GSH: glutathione
HBA: p-hydroxybenzyl alcohol
LDW: Liuwei Dihuang Wang
LTP: long-term potentiation
MAO: monoamine oxidase
MCA-Hg: 8-O-E-p-methoxycinnamoylharpagide
MDA: malondialdehyde
NMMA: N-methyl-d-aspartic acid
PD/PT ratio: protopanaxadiol/protopanaxatriol ratio
RGTS: red ginseng total saponins
RNA: ribonucleic acid
RT-PCR: reverse transcriptase polymerase chain reaction
TAO: superoxide dismutase
TBARS: thiobarbituric acid reactive species

Introduction
Amnesia is characterized by the inability to form memories or total or partial loss of memory secondary to cerebral malfunction following degenerative diseases such as Alzheimer’s disease (AD), cerebral infections such as herpes or encephalitis, traumatic injuries such as stroke, alcohol or drug abuse and emotional events such as psychological trauma. The limbic system, comprised of the hippocampus, amygdala and parts of the cortex, is responsible for retrieving memory. Memory for-
information can be broadly categorized into three distinctive stages, namely learning acquisition, memory consolidation and retrieval. Despite the extensive causes of amnesia, the major affected brain regions are usually the subcortical region called the diencephalon and the cortical region called the medial temporal lobe [1]. The definition of amnesia can vary considerably according to different agreements on the term. This review focuses on recent literature on anterograde amnesia, which is the impaired ability to learn new information following the onset of amnesia, and retrograde amnesia, which is the impaired ability to recall past events and previously familiar information. Although amnesia is easily confused with dementia, they are distinguishable from each other. Unlike dementia, the amnesic memory loss does not affect a person’s intelligence, general knowledge, awareness, attention span, judgment, personality or identity. Amnesia can happen to people at any age which can be a heavy burden to family members and the society, and requires extensive medical care and support schemes.

No conventional or alternative therapy is currently available to cure amnesia. Current therapeutic strategies for amnesia are mainly focused on enhancing or restoring cerebral circulation, restoring the level of neurotransmitters including acetylcholine (ACh), scavenging free radicals and restoring cell membrane fluidity. In the management of amnesia as well as AD, sustained treatment with cholinesterase inhibitors including donepezil, rivastigmine, galantamine and tacrine have been used. However, these drugs have questionable efficacy and may induce severe side effects including nausea, vomiting, diarrhea and muscle cramps. Since ancient times, herbal medicines have been documented and used for nootropics (cognition-enhancing agents which aim at improving concentration, memory retention and problem-solving ability). In China, for example, the use of Panax ginseng C.A. Meyer (Araliaceae) to promote health and improve learning and memory is well documented [2–4]. Nowadays, Ginkgo biloba L. (Ginkgoaceae) extract (GBE) has been widely used as a health supplement to promote memory and standardized GBE has been approved in the German Commission E Monograph for the symptomatic treatment of the memory impairment, concentration difficulties and depression that result from organic brain disease [5]. In the past few years, the uses of herbal medicines for the treatment of cognitive impairments such as amnesia, AD or dementia have been widely studied; some drugs developed from herbs have shown prominent clinical improvements. A good example is galantamine (also known as galanthamine), which is an alkaloid extracted from the bulbs of Galanthus nivalis L. (Amaryllidaceae) with a promising effect for the treatment of AD as a competitive reversible acetylcholinesterase (ACHE) inhibitor [6]. It inhibits the hydrolysis of endogenous ACh and enhances the release of ACh by modulating nicotinic receptors in cholinergic system, thereby increasing the availability of ACh in the postsynaptic membrane. It is now one of the four cholinesterase inhibitors approved by the Food and Drug Administration (FDA) for the treatment of dementia [7]. In addition, galantamine is able to cross the blood–brain barrier (BBB) and therefore has high bioavailability.

Over the years, scientists have exerted great efforts to identify new anti-amnesic compounds from herbal medicines to meet the unmet medical needs. Potential new drugs from herbal medicines may be relevant in the treatment of cognitive disorders including amnesia. Herbal medicines can not only act synergistically with other components from the same herb, but also enhance the activity of active components from other herbs in accordance with traditional practices including traditional Chinese and Ayurvedic medicines. Herbal medicines may confer anti-amnesic protection by scavenging free radicals, enhancing cerebral blood flow, restoring ribonucleic acid (RNA) and protein levels. Besides, neurotransmitter systems were shown to play pivotal roles in cognitive processes where interactions between systems give rise to memory formation, consolidation and retrieval. Meanwhile, deficits in cholinergic, GABAergic, glutaminergic, serotonergic, catecholaminergic and histaminergic neurotransmissions can account at least partly for the pathophysiology of amnesia. Long-term potentiation is an important process in learning and memory, the action of which can be affected by changes in cholinergic, dopaminergic, noradrenergic and serotonergic systems [8–12]. Numerous research findings have revealed the involvement of different neurotransmitters in memory processes. Glutamate, GABA, dopamine and acetylcholine were shown to have stronger impacts on cognitive processes than serotonin and norepinephrine [13]. As reported in a number of experimental paradigms, administration of NMDA antagonists like MK-801 and APV, AMPA antagonists like NBQX and CNQX, GABA A agonists like diazepam and muscimol, GABA B antagonist (CGP 463 81) and agonist (baco- clen), muscarinic antagonists like scopolamine and atropine, nicotinic antagonist like mecamylamine, serotonin 5-HT A agonist like alaprapocele and bupipron, norepinephrine α-1 antagonist like prazosin, α-2 agonist like dexmedetomidine and a β antagonist like propranolol, and dopamine D-2 antagonists like haloperidol and sulpiride led to memory impairment, while the uses of AMPA agonist like piperidine and norepinephrine α-1 agonist like St-587 resulted in memory enhancement [13].

The literature was retrieved by searches of the most popular database Pubmed, using different combinations of keywords including “herbs”, “herbal medicines”, “amnesia”, “memory enhancement”, “anti-oxidant”, “cholinergic”, “GABAergic”, “glutaminergic”, “serotonergic”, “catecholaminergic” and “histaminergic”. The search covered the period from 1983 to March 2009. Reviews and research articles related to retrograde and anterograde amnesia were included. Additional papers of interest were retrieved from the reference lists of the above articles. We manually retrieved some recognized articles which are not available electronically. To construct a meaningful discussion on anti-amnesic effect of herbal medicine, studies totally without any attempt at mechanistic elucidation were excluded.

This paper summarizes the research findings and provides an overview of herbal medicines as treatments for both retrograde and anterograde amnesia. In this review, we present evidence for the potential benefit of herbal medicines in treating cognitive impairment following amnesia with special emphasis on actions through neurotransmitter systems. We first review the efficacies of various herbal medicines in in vivo and in vitro models of amnesia. Then, we discuss the characteristics of herbs which are suitable for treating amnesia, current issues and future perspectives for research and development of herbal medicines against amnesia.
chemical agents possess different mechanistic actions on neural systems and intervene in the memory formation process at different stages. Scopolamine is a muscarinic acetylcholine receptor antagonist that induces memory deficits and is used widely to investigate cholinergic influence on learning ability in experimental animals. Scopolamine impairs learning acquisition that shortens the step-through latency in a passive avoidance task [14]. In the process of memory consolidation, new protein transcriptions and synthesis are needed [15]. Cycloheximide is an inhibitor of protein synthesis which impairs the memory consolidation process [16, 17]. Apomorphine is used to impair the process of memory retrieval [18]. At high doses, it is a dopamine receptor agonist that increases dopaminergic activity and impairs memory retrieval in rodents. p-Chloroamphetamine is a serotonergic releaser which enhances serotonergic activity and is used to impair acquisition performance in animal models [19]. Mecamylamine is a nicotinic cholinergic antagonist. Blockade of the nicotinic receptor impairs learning acquisition [20]. Dizocilpine is also known as MK-801, a noncompetitive NMDA receptor antagonist which impairs memory reactivation [21]. Ibotenic acid impairs reference and working memory as revealed by poor performance in both spatial and associative radial maze tasks [22, 23]. It also provokes neuronal necrosis by overstimulation of N-methyl-D-aspartate (NMDA) receptors and elicits a sign of Alzheimer-type neurodegeneration [22]. Amnesia was induced by microinjection of ibotenic acid into the medial septal area. Ibotenic acid causes impairment of memory acquisition by decreasing ChAT activities in the hippocampus and frontal cortex [24].

Mechanisms of Actions Concluded from Animal Studies

Many herbs have been reported to improve memory and learning. They work through different mechanisms by affecting cholinergic, GABAergic, glutaminergic, serotonergic, histaminergic and catecholaminergic nervous systems. Natural products isolated from single herbs have been widely examined for their efficacies on amnesia. Through the isolation and structural determination, new drug candidates with promising anti-amnesic effects were identified. Interestingly, extracts of herbal formulations in traditional practice have also been studied and showed significant effects. These herbs and herbal formulae with anti-amnesic effects are introduced and have been listed in Table 1.

Action through cholinergic nervous system

Cholinergic transmission in the brain cortical and hippocampal regions plays a fundamental role in memory [25]. Improved cholinergic neurotransmission can be achieved by increasing stimulation of cholinergic receptors and increasing the availability of ACh in the neuronal synaptic cleft. Muscarinic M2 autoreceptor inhibitors increase the release of ACh [26] while cholineresterase inhibitors decrease the breakdown of ACh. Cholinesterase inhibitors that block AChE and/or butryrylcholinesterase are the most common pharmacotherapy for amnesia, dementia and Alzheimer’s disease. Several AChE inhibitors have been approved by the FDA for alleviation of symptoms; however, permanent improvement has not yet been achieved. The use of tacrine, the first licensed AChE inhibitor, is highly restricted due to its hepatotoxicity [27, 28].

Angelica acutiloba (Siebold & Zucc.) Kitag. (Apiaceae) and Paeonia lactiflora Pall. (Paeoniaceae): A traditional formulation, Shimosu-to, is composed of four herbs namely A. acutiloba (Japanese angelica root), P. lactiflora (peony root), Cnidium officinale Makino. (Umbelliferae) and Rehmannia glutinosa Libosch. (Scrophulariaceae). Peony root extract and Japanese angelica root extract have been shown to significantly attenuate scopolamine-induced amnesia in rats [29]. As indicated by the performance of paenoflinorin [11] (Fig. 1) in treated rats in the eight arm radial maze, it can significantly attenuate the scopolamine-induced amnesia. Paenoflinorin helped recover the scopolamine-induced decline of ACh content in the striatum. However, active components of the other three herbs in this formulation were not resolved and their roles in memory-enhancing effect remain unclear.

Angelica gigas Nakai. (Umbelliferae): Decursin (2) (Fig. 1), a major coumarin constituent of A. gigas, significantly ameliorated scopolamine-induced amnesia in passive avoidance test and Morris water maze test. Decursin exerted its anti-amnesic activity in vivo in part by inhibiting AChE activity in the hippocampus [30]. Nodakenin (3) (Fig. 1), a coumarin, is also isolated from the roots of A. gigas. Rats/mice treated with nodakenin antagonized the scopolamine-induced cognitive impairments in passive avoidance and Y-maze test. In the Morris water maze test, the escape latency during training was reduced whereas swimming times and distances within the target zone were increased in the nodakenin-treated amnesic group. Nodakenin exhibited an inhibitory effect on AChE activity in vitro and ex vivo studies. It is suggested that nodakenin conferred beneficial effect against cognitive impairment through enhancement of cholinergic signaling [31]. In summary, decursin and nodakenin derived from A. gigas are two active ingredients with promising anti-amnesic activity. Of note, decursin showed a higher AChE inhibitory effect than the positive control velnacrine (a known AChE inhibitor). Decursin, a chemical derivative of decursinol which was present in the highest quantity in A. gigas, with the addition of an isoprenyl unit at C-6 of coumarin derivatives, facilitates its penetration through cellular membranes like BBB [32].

Acorus gramineus Soland. (Araeaceae): Acori graminei rhizoma (AGR) is the dried rhizomes of Acorus gramineus Solander (Araeaceae), which have been shown to have a protective effect against stroke, AD and vascular dementia [33–35]. AGR alleviated learning and memory deficits as revealed by the improved performance on the Morris Water maze. It conferred neuroprotection partly through attenuation of ibotenic acid-induced decrease of acetylcholinergic neurons in the hippocampus [36].

Angelica sinensis (Oliv.) Diels. (Apiaceae) and Cnidium officinale Makino. (Umbelliferae): Butyridenephthalide (BDPH) (4) (Fig. 1) is an active lipophilic ingredient isolated from A. sinensis and C. officinale. BDPH attenuated scopolamine and/or mecamylamine-induced acquisition impairment. It was found that a peripheral cholinergic muscarinic receptor antagonist (scopolamine methylbromide) did not inhibit the counteracting effect of BDPH against scopolamine-induced acquisition impairment. BDPH attenuated the AF64A (central acetylcholinergic neurotransmitter) induced cognitive impairment. These findings suggest that the cognitive enhancing effect of BDPH acted through the activation of the central muscarinic and nicotinic receptors but not the peripheral cholinergic neuronal systems [37].

Angelica sinensis (Oliv.) Diels. (Apiaceae) and Ligusticum wallichii Franch. (Apiaceae): Ferulic acid (5) (Fig. 1) can be isolated from A. sinensis, L. wallichii and many other plants. Ferulic acid reversed the scopolamine- and cycloheximide-induced cognitive impairment but not the p-chloroamphetamine-induced impairment by activation of the cholinergic system and enhancement of brain microcirculation [38].
### Table 1 Summary on anti-amnesic effects of herbal extracts.

<table>
<thead>
<tr>
<th>Name of herbs/formulae</th>
<th>Active compound or fraction, effective dose and treatment duration</th>
<th>Possible mechanisms on nervous system</th>
<th>Types of models</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acorus gramineus Soland., Araceae</td>
<td>Methanol extract of Acorus gramineus rhizome (AGR); 100 mg/kg, i.p.; 21 days</td>
<td>Attenuated ibotenic acid-induced decrease of acetylcholinergic neuron in hippocampus</td>
<td>Ibotenic acid (4 µg/µL artificial CSF, microinjection into medial septal area) induced in rats</td>
<td>[36]</td>
</tr>
<tr>
<td>Angelica gigas Nakai., Umbelliferae</td>
<td>Decursin; 1 and 5 mg/kg, i.p.; single administration</td>
<td>Inhibited AChE activity by 34% in the hippocampus</td>
<td>Scopolamine (1 mg/kg, i.p.) induced in mice</td>
<td>[31]</td>
</tr>
<tr>
<td>Cnidium officinale Makino., Umbelliferae</td>
<td>Nodiakenin; 10 mg/kg, p.o.; single administration</td>
<td>Inhibited AChE activity in in vitro study (IC50 = 84.7 µM); Inhibited AChE activity for 6h in ex vivo study</td>
<td>Scopolamine (1 mg/kg, i.p.) induced in mice</td>
<td>[32]</td>
</tr>
<tr>
<td>Angelica sinensis (Oliv.) Diels., Apiaceae</td>
<td>n-Butylenediphthalide (BDPH); 50 or 100 mg/kg, i.p.; single administration</td>
<td>By activation of central (via muscarinic and nicotinic receptors) but not the peripheral cholinergic neuronal systems</td>
<td>Scopolamine (1.0 mg/kg, i.p.) or mecamylamine (10.0 mg/kg, i.p.) or scopolamine (0.3 mg/kg, i.p.) plus mecamylamine (3 mg/kg, i.p.) induced in rats</td>
<td>[37]</td>
</tr>
<tr>
<td>Angelica sinensis (Oliv.) Diels., Apiaceae</td>
<td>Ferulic acid; 50 and 100 mg/kg, i.p.; single administration</td>
<td>By activation of the cholinergic system and enhancement of brain microcirculation</td>
<td>Scopolamine (1.0 mg/kg, i.p.) or cycloheximide (1.5 mg/kg, s.c.) induced in rats</td>
<td>[38]</td>
</tr>
<tr>
<td>Bacopa monniera (L.) Penn.syn., Scrophulariaceae</td>
<td>Standardized extract containing 55.35% bacossides; 120 mg/kg, p.o., 60 min, single administration</td>
<td>Act through GABA-benzodiazepine pathway</td>
<td>Diazepam (1.75 mg/kg, i.p.) induced in mice</td>
<td>[70]</td>
</tr>
<tr>
<td>Coptis chinensis Franch., Ranunculaceae</td>
<td>Berberine; 0.1 or 0.5 g/kg, p.o.; 7-day or 14-day</td>
<td>Enhanced peripheral and central cholinergic neuronal system activities</td>
<td>Scopolamine (1.0 mg/kg, i.p.) induced in rats</td>
<td>[39]</td>
</tr>
<tr>
<td>Cordyceps yanhusuo W. T. Wang., Papaveraceae</td>
<td>Pseudocoptisine; 2.0 mg/kg, p.o.; 0.5, 1, 3, 6 or 12 hours</td>
<td>Inhibited AChE activity</td>
<td>Scopolamine (1.0 mg/kg, i.p.) induced in rats</td>
<td>[40]</td>
</tr>
<tr>
<td>Cnidium monnieri (L.) Cuss., Apiaceae</td>
<td>Osthole; 3 or 10 mg/kg, s.c.; 3 days in rats</td>
<td>Mediated in part by activation of the central cholinergic neuronal system</td>
<td>Scopolamine (0.5 mg/kg, i.p.) induced in rats</td>
<td>[41]</td>
</tr>
<tr>
<td>Desmodium gangeticum (L.) DC., Fabaceae</td>
<td>Aqueous extract; 50, 100 or 200 mg/kg, p.o., 7 days</td>
<td>Decreased AChE activity</td>
<td>Scopolamine (0.4 mg/kg, i.p.) induced in mice</td>
<td>[42]</td>
</tr>
<tr>
<td>Foeniculum vulgare Mill., Apiaceae</td>
<td>Methanolic extract of the whole plant; 8 days</td>
<td>Inhibited AChE activity</td>
<td>Scopolamine (0.4 mg/kg, i.p.) induced in mice</td>
<td>[43]</td>
</tr>
<tr>
<td>Gastrodia elata Bl., Orchidaceae</td>
<td>p-Hydroxybenzyl alcohol (HBA); 1, 5 or 25 mg/kg, p.o.; single administration</td>
<td>Acted through suppressing dopaminergic and serotonergic activities</td>
<td>Scopolamine (1.0 mg/kg, i.p.) induced in rats</td>
<td>[79,80]</td>
</tr>
<tr>
<td>Geissospermum vellosii Allem., Apocynaceae</td>
<td>Ethanolic extract of G. vellosii stembarks; 30 mg/kg, i.p. 45 min</td>
<td>Imposed anticholinesterase activity</td>
<td>Scopolamine (1.0 mg/kg, i.p.) induced in mice</td>
<td>[44]</td>
</tr>
<tr>
<td>Ginkgo biloba L., Ginkgoaceae</td>
<td>Whole extract; 30 and 60 mg/kg; 7 consecutive days (once per day)</td>
<td>Inhibited AChE activity in in vitro study (IC50 = 268.33 µg);</td>
<td>Scopolamine (3.0 mg/kg, i.p.) induced in mice</td>
<td>[45]</td>
</tr>
<tr>
<td>Lindera umbellulata, Rutaceae</td>
<td>Whole extract; 40 and 90 mg/kg, oral, 7 days</td>
<td>Acted through glutamatergic system enhancement</td>
<td>MK-801 (0.06 mg/kg for 1 h or 0.1 mg/kg for 1 day, i.p.) induced in rats</td>
<td>[75]</td>
</tr>
<tr>
<td>Hypericum perforatum L., Guttiferae</td>
<td>Ethanolic extract; 4.0, 8.0, 12.0, and 25.0 mg/kg, i.p.; 1 day, single administration</td>
<td>Acted through adrenergic and serotoninergic 5-HT1A receptors</td>
<td>Scopolamine (3.0 mg/kg, i.p.) induced in mice</td>
<td>[82]</td>
</tr>
<tr>
<td>Liuwei Dihuang Wang</td>
<td>Aqueous or ethanol extract; 1 or 2 g/kg, p.o.; single administration</td>
<td>By activating peripheral cholinergic neuronal system and modulating the central nervous system</td>
<td>Cycloheximide (1.5 mg/kg, s.c.) induced in rats</td>
<td>[47]</td>
</tr>
<tr>
<td>Aqueous extract; 1 g/kg for 7 days or 0.1 g/kg for 14 days, p.o.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aqueous extract; 1 g/kg for 7 days; 0.01 g/kg for 14 days</td>
<td>not mentioned</td>
<td>Scopolamine (1.0 mg/kg, i.p.) induced in rats</td>
<td>[48]</td>
<td></td>
</tr>
<tr>
<td>Aqueous extract; 0.1–1.0 g/kg for 7 days; 0.01 g/kg for 14 days</td>
<td>not mentioned</td>
<td>p-Chloroamphetamine (2.5 mg/kg) induced in rats</td>
<td>[48]</td>
<td></td>
</tr>
</tbody>
</table>

... (continued)
Table 1 (continued)

<table>
<thead>
<tr>
<th>Name of herbs/formulae</th>
<th>Active compound or fraction, effective dose and treatment duration</th>
<th>Possible mechanisms on nervous system</th>
<th>Types of models</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lonicerajaponica Thunb., Caprifoliaceae</td>
<td>Luteolin; 5 or 10 mg/kg, i. p.; single administration</td>
<td>Enhanced activities of central muscarinic and nicotinic receptors</td>
<td>Scopolamine (0.5 mg/kg, i. p.) induced in rats</td>
<td>[49]</td>
</tr>
<tr>
<td></td>
<td>Luteolin; 5 or 10 mg/kg, p. o.; single administration</td>
<td>Modulated microvascular function; Increased in regional cerebral blood flow; Efficient clearance of reactive oxygen species; Restored ACh level and reduced AChE activity; Increased in brain-derived neurotrophic factor level and its receptor tyrosine kinase B expression in cerebral cortex</td>
<td>Amyloid β (aggregated form, 3 µl, icv) induced in mice</td>
<td>[50]</td>
</tr>
<tr>
<td>Murraya koenigi (L.) Roxb., Rutaceae</td>
<td>Leaves of M. koenigi (grinded into powder), 2, 4 and 8% w/w, p. o.; single dose for 30 days</td>
<td>Inhibited brain cholinesterase activity</td>
<td>Scopolamine (0.4 mg/kg, i. p.) induced in mice</td>
<td>[51]</td>
</tr>
<tr>
<td>Nardostachys jatamansi DC., Valerianaceae</td>
<td>Ethanolic extract; 200 mg/kg, p. o.; 8 days</td>
<td>Facilitated cholinergic transmission and acted through antioxidation</td>
<td>Scopolamine (0.4 mg/kg, i. p.) or diazepam (1.0 mg/kg, i. p.)</td>
<td>[52]</td>
</tr>
<tr>
<td>Nelumbo nucifera Gaerth., Nymphaeaceae</td>
<td>Lyophilized aqueous extract of N. nucifera semen; 1 g/kg, i. p.; single administration</td>
<td>Inhibited AChE activity and increased CHAT expression</td>
<td>Scopolamine (1 mg/kg, i. p.) induced in rats</td>
<td>[53]</td>
</tr>
<tr>
<td>Paeonia lactiflora Pall., Paeoniaceae</td>
<td>Whole extract of peony root; 0.25 and 1 g dried herb/kg, p. o.</td>
<td>Reversed scopolamine-induced decrease in ACh content in striatum</td>
<td>Scopolamine (0.3 mg/kg, i. p.) induced in rats</td>
<td>[29]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Panax ginseng C. A. Mey., Araliaceae</td>
<td>Red ginseng total saponins; single: 200 mg/kg, p. o.; or repeated: 200 mg/kg, p. o.; 7 days</td>
<td>Acted through catecholaminergic neuronal system</td>
<td>Ethanol (3 g/kg, p. o.) induced in rats</td>
<td>[87]</td>
</tr>
<tr>
<td>Rb1</td>
<td></td>
<td>Enhanced level of ACh in the CNS (through increasing acetylcholinesterase activity or inhibiting AChE activity); Increased protein biosynthesis</td>
<td></td>
<td>[57]</td>
</tr>
<tr>
<td>Rg1</td>
<td></td>
<td>Enhanced level of ACh in the CNS (through increasing acetylcholinesterase activity or inhibiting AChE activity); Increased protein biosynthesis</td>
<td></td>
<td>[57]</td>
</tr>
<tr>
<td>Rg3(R), Rg3(S) and Rg5/Rk1; 10 mg/kg, p. o.; once a day for 4 days</td>
<td>Conferred neuroprotection partly through anti-excitotoxic abilities</td>
<td>Ethanol (3 g/kg, p. o.) induced in mice</td>
<td></td>
<td>[76]</td>
</tr>
<tr>
<td>Rg3(S) and Rg5/Rk1; 10 mg/kg, p. o.; once a day for 4 days</td>
<td>Conferred neuroprotection partly through anti-excitotoxic abilities</td>
<td>Scopolamine (3 mg/kg, i. p.) induced in mice</td>
<td></td>
<td>[76]</td>
</tr>
<tr>
<td>Polygala tenuifolia Willd., Polygalaceae</td>
<td>Methanolic extract (50 mg/kg), Acylated oligosaccharide-containing fraction (25 mg/kg), p. o.; 1 day, single administration</td>
<td>Enhanced central cholinergic system</td>
<td>Scopolamine (0.2 mg/kg) induced in mice</td>
<td>[59]</td>
</tr>
<tr>
<td></td>
<td>Tenuifoliside B (3 or 10 mg/kg), p. o.; 1 day, single administration</td>
<td>Enhanced central cholinergic system</td>
<td>Scopolamine (1.0 mg/kg) induced in rats</td>
<td></td>
</tr>
<tr>
<td>Polygonatum multiflorum Thunb., Polygonaceae</td>
<td>Emorodin; 3, 15 or 30 mg/kg, p. o.; single administration</td>
<td>The beneficial effects were amplified by serotoninergic 5-HT_{1A} receptor partial agonist (8-OH-DPAT) and 5-HT_{2} receptor antagonist (ritanserin) but reduced by muscarinic receptor antagonist (scopolamine)</td>
<td>Cycloheximide (1.0 mg/kg, s.c.) induced in rats</td>
<td></td>
</tr>
<tr>
<td>Pueraria lobata (Willd.) Ohwi, Fabaceae</td>
<td>Puerarin; 25–50 mg/kg, i. p.; single administration</td>
<td>Enhanced cholinergic activity via nicotinic receptors (but not muscarinic), activated NMDA receptors and decreased serotonergic neuronal activity</td>
<td>Mecamylamine (10 mg/kg, i. p.), p-chloroamphetamine (5 mg/kg, i. p.) or dizocilpine (i.e. MK-801, 0.1 mg/kg, i. p.) induced in rats</td>
<td></td>
</tr>
</tbody>
</table>

Hsieh MT et al. Review on Experimental... Planta Med 2010; 76: 203–217
Coptis chinensis Franch. (Ranunculaceae): Berberine (6) (Fig. 1), isolated from C. chinensis, was shown to attenuate scopolamine-induced amnesia significantly. The beneficial effect was suggested to be linked to the increase in peripheral and central cholinergic neuronal system activities [39].

Corydalis yanhusuo W.T. Wang. (Papaveraceae): Pseudocoptisine is a quaternary benzylisoquinoline alkaloid isolated from the tuber of C. yanhusuo. Pseudocoptisine conferred anti-amnesic activity against scopolamine-induced learning and memory impairments partially via inhibition of AChE activity in a dose-dependent manner [40]. It is postulated that the detected AChE inhibitory activity might be traced back to the presence of a benzylisoquinoline alkaloid.

**Table 1** (continued)

<table>
<thead>
<tr>
<th>Name of herbs/formulae</th>
<th>Active compound or fraction, effective dose and treatment duration</th>
<th>Possible mechanisms on nervous system</th>
<th>Types of models</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pueraria thunbergiana (Siebold, &amp; Zucc.) Benth., Fabaceae</td>
<td>Methanol extract of P. thunbergiana; 500 µg/mL in assay mixture</td>
<td>By activation effect (46%) on acetylcholinesterase in vitro;</td>
<td>Scopolamine (1.0 mg/kg, s.c.) induced in mice</td>
<td>[61]</td>
</tr>
<tr>
<td>Daidzein; 4.5 mg/kg, p.o., 4 weeks</td>
<td></td>
<td>By acting as a choline acetyltransferase activator for ACh biosynthesis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salvia miltiorrhiza Bge., Labiatae</td>
<td>Tanshinone I (2 or 4 mg/kg, p.o.); single administration</td>
<td>Slightly inhibited AChE activity in vitro but not ex vivo</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tanshinone I (2 mg/kg, p.o.); single administration</td>
<td>Posed GABA-A/benzodiazepine receptor ligand property</td>
<td>Diazepam (1 mg/kg, i.p.) induced in mice</td>
<td>[62]</td>
</tr>
<tr>
<td></td>
<td>Tanshinone II A (10 or 20 mg/kg, p.o.); single administration</td>
<td>Posed GABA-A/benzodiazepine receptor ligand property</td>
<td>Diazepam (1 mg/kg, i.p.) induced in mice</td>
<td>[62]</td>
</tr>
<tr>
<td></td>
<td>Tanshinone II A (10 or 20 mg/kg, p.o.); single administration</td>
<td>Slightly inhibited AChE activity in vitro but not ex vivo</td>
<td>Scopolamine (1 mg/kg, i.p.) induced in mice</td>
<td>[62]</td>
</tr>
<tr>
<td></td>
<td>Cryptotanshinone (10 mg/kg, p.o.); single administration</td>
<td>Inhibited AChE activity for 3 h in ex vivo study; Inhibitory effect on AChE in vitro (IC$_{50}$ value 25 µM)</td>
<td>Scopolamine (1 mg/kg, i.p.) induced in mice</td>
<td>[62]</td>
</tr>
<tr>
<td></td>
<td>15,16-dihydrotanshinone I (2 or 4 mg/kg, p.o.); single administration</td>
<td>Inhibited AChE activity for 6 h in ex vivo study; Inhibitory effect on AChE in vitro (IC$_{50}$ value 25 µM)</td>
<td>Scopolamine (1 mg/kg, i.p.) induced in mice</td>
<td>[62]</td>
</tr>
<tr>
<td>Salvia triilobo L., Labiatae</td>
<td>Hydroalcoholic extract; 200 or 400 mg/kg, 1 day, single administration</td>
<td>Inhibited AChE activity; Posed antioxidant activity</td>
<td>Scopolamine (1.0 mg/kg, i.p.) induced in mice</td>
<td>[63]</td>
</tr>
<tr>
<td>Schisandra chinensis (Turcz.) Baill., Tremellaceae</td>
<td>Gomisin A; 5 mg/kg, p.o.; single administration</td>
<td>Inhibited AChE activity in vitro study (IC$_{50}$ = 15.5 µM);</td>
<td>Scopolamine (1 mg/kg, i.p.) induced in mice</td>
<td>[66]</td>
</tr>
<tr>
<td></td>
<td>Water layer of fruit of S. chinensis; 10 and 25 mg/kg, p.o.; single administration</td>
<td>The ameliorating effect was amplified by treatment with serotonergic 5-HT$_2$ receptor antagonist (ritanserin)</td>
<td>Cycloheximide (1.5 mg/kg, s.c.) induced in rats</td>
<td>[79]</td>
</tr>
<tr>
<td>Scrophularia buergeriana Miquel., Scrophulariaceae</td>
<td>(1) E-harpagoside; 2 mg/kg, p.o.; single administration</td>
<td>Increased glutathione reductase and SOD as well as decreased GSH and TBARS activities or contents;</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(2) 8-O-E-p-methoxycinnma moyl-harpagide (MCA-Hg); 2 mg/kg, p.o.; single administration</td>
<td>Inhibited activity of AChE within the cortex and hippocampus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scutellaria baicalensis Georgi., Lamiaceae</td>
<td>Oxoryl A (5 mg/kg); single administration</td>
<td>Acted through GABAergic nervous system</td>
<td>Scopolamine (1 mg/kg, i.p.) induced in mice; or Diazepam (1 mg/kg, i.p.) induced in mice</td>
<td>[71]</td>
</tr>
<tr>
<td>Teucrium polium L., Lamiaceae</td>
<td>Hydroalcoholic extract; 200 or 400 mg/kg; 1 day, single administration</td>
<td>Inhibited AChE activity; Posed antioxidant activity</td>
<td>Scopolamine (1.0 mg/kg, i.p.) induced in mice</td>
<td>[63]</td>
</tr>
<tr>
<td>Thespesia populnea Milo., Malvaceae</td>
<td>Ethanolic extract; 200 or 400 mg/kg, p.o.; 7 days</td>
<td>Reduced anticholinesterase activity</td>
<td>Scopolamine (0.4 mg/kg, i.p.) induced in mice</td>
<td>[67]</td>
</tr>
<tr>
<td>Tremella fuciformis Berk., Tremellaceae</td>
<td>Aqueous extract; 100 or 400 mg/kg, p.o.; 14 days</td>
<td>Acted through cholinergic nervous system</td>
<td>Scopolamine (2 mg/kg, s.c.) induced in rats</td>
<td>[68]</td>
</tr>
<tr>
<td></td>
<td>Aqueous extract; 0.01, 0.05, 0.1 and 1 µg/mL</td>
<td>Promoted neurite outgrowth of PC12h cells</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uncariae ramulus et Uncus., Rubiaceae</td>
<td>Methanolic extract; 100 mg/kg, i.p.; 21 days</td>
<td>Reduced the loss of cholinergic immunoreactivity in the hippocampus</td>
<td>Ibotoic acid (0.1 µL at concentration 4 µg/µL, icv) induced in rat</td>
<td>[69]</td>
</tr>
<tr>
<td>Uncaria rhynchophylla (Miq.) Jacks., Rubiaceae</td>
<td>Methanolic extract (250 mg/kg) or alkaloid fraction (25 or 50 mg/kg), p.o.; 7 days</td>
<td>Restored the decrease in glutamic acid and 5-hydroxytryptamine</td>
<td>Ethanol [3 g/kg at concentration 38% (v/v)] induced in mice</td>
<td>[77]</td>
</tr>
</tbody>
</table>
part by mediating the activation of the central cholinergic neuronal system [41].

**Desmodium gangeticum** (L.) DC. (Fabaceae): Its aqueous extract reversed scopolamine induced amnesia by decreasing whole brain AChE activity [42].

**Foeniculum vulgare** Mill. (Apiaceae): A methanolic extract of the whole plant of *F. vulgare* ameliorated the amnesic effect of scopolamine by increasing step-down latency and inhibiting AChE activity [43].
**Geissospermum vellosii** Allem. (Apocynaceae): Pretreatment with an ethanolic extract of *G. vellosii* stem barks reduced scopolamine-induced amnesia as evidenced in passive avoidance and Morris water maze tests. *G. vellosii* showed potent anticholinesterase activity in vitro with a mean IC₅₀ value of 39.3 μg/mL, where geissospermine was identified as the main cholinesterase inhibitor [44].

**Ginkgo biloba** L. (Ginkgoaceae): Rats/mice pretreated with *G. biloba* extract resulted in significant inhibition of AChE activity in vivo and ex vivo [45]. It is postulated that the reduced AChE activity caused an increase in ACh level, which maintained learning and memory functions. The more pronounced anti-AChE activity was found in the detergent soluble fraction which mainly consists of the G4 form of the AChE of *G. biloba*, rather than the salt soluble fraction which mainly consists of the G1 isoform of the AChE. This implies that the G4 isoform of AChE is important in maintaining learning and memory functions.

**Huperzia serrata** (Thunb.) Trev. (Lycopodiaceae): (−)-Huperzine A [8] (Fig. 1) is a natural Lycopodium alkaloid, extracted from *H. serrata*. Rats pretreated with (−)-huperzine A before scopolamine injection resulted in improvement of reference memory and working memory, as shown in radial maze performance. It was reported that (−)-huperzine A possessed unique anti-AChE activity [46].

**Liuwei Dihuang Wang** (LDW): LDW is a herbal formulation consisting of six herbs, namely Rhizoma of *Rehmannia glutinosa* Libosch. (Gesneriaceae), Fructus of *Cornus officinalis* Sieb. et Zucc. (Cornaceae), Radix of *Dioscorea opposita* Thunb. (Dioscoreaceae), Rhizoma of *Alisma orientalis* (Sam.) Juzep. (Alismataceae), Cortex of *Paonia suffruticosa* Andr. (Paeoniaceae) and *Poria cocos* (Schw.) Wolf. (Polyporaceae). LDW ameliorated cycloheximide, scopolamine- or p-amphetamine-induced amnesia [47, 48]. The ameliorating effects of LDW were blocked by a muscarinic antagonist (scopolamine), a peripheral cholinergic antagonist (scopolamine methylbromide), a serotonin precursor (5-hydroxytryptamine), a serotonin releaser (p-chloroamphetamine), a GABA₄ receptor antagonist (bicuculline) and a GABA₉ receptor antagonist (baclofen). These findings collectively implied that the ameliorating effects of LDW may be triggered by activating the peripheral cholinergic neuronal system and modulating the central nervous system.

**Lonicera japonica** Thunb. (Caprifoliaceae): Luteolin [9] (Fig. 1) is usually found in celery, green pepper, perilla leaf and seed, chamomile tea and *L. japonica*. Luteolin reversed learning acquisition impairment induced by cholinergic neurotoxin, muscarinic (scopolamine hydrobromide) or nicotinic receptor antagonists. However, luteolin does not protect the brain from learning acquisition impairment induced by N-methyl bromide, dopaminergic neurotoxin (6-hydroxydopamine, 6-OHDA) and serotonergic neurotoxin (5,7-dihydroxytryptamine, 5,7-DHT). These findings suggested that luteolin protected the brain from scopolamine-induced learning acquisition impairment by enhancing the activities of central muscarinic and nicotinic receptors [49]. In another study, luteolin was shown to confer robust neurovascular protection in Abeta(25–35)-induced amnesia as evidenced by improvement in spatial learning and memory capabilities. This protection was attributed to a modulated microvascular function and increased regional cerebral blood flow, efficient clearance of reactive oxygen species, restored ACh level and reduced AChE activity, as well as increased brain-derived neurotrophic factor level and its receptor tyrosine kinase B expression in cerebral cortex [50].

**Murraya koenigii** (L.) Roxb. (Rutaceae): Leaves of *M. koenigii* were found to alleviate scopolamine-induced amnesia in young (3–4 months) and aged (12–15 months) mice. Inhibited brain cholinesterase activity was attributed to this protection [51].

**Nardostachys jatamansi** DC. (Valerianaceae): Its ethanolic extract has been shown to reverse scopolamine or dizocilpine-induced amnesia. This improvement can be attributed to facilitated cholinergic transmission [52] and its antioxidant property [52].

**Nelumbo nucifera** Gaertn. (Nymphaeaceae): *N. nucifera* semen has been reported to have anti-diarrheal, anti-ganacratia, and tranquilizer-like activities. Lyophilized aqueous extract of *N. nucifera* semen attenuated scopolamine-induced deficit in which the AChE activity of the *N. nucifera* treated group decreased to 7.35% and CHAT-positive neurons in the *N. nucifera* treated group increased by 51.02% compared with the control group. By inhibiting AChE activity and inducing CHAT expression, *N. nucifera* conferred anti-amnesic protection [53].

**Panax ginseng** C. A. Meyer (Araliaceae): Ginsenosides, the sapo- nins of ginseng, are extracted from the root and rhizome of *P. ginseng*. The neuroprotective effects of ginsenosides have been widely studied in different models of neurological deficits like cerebral ischemia, Parkinson’s disease and memory impairments. Ginsenoside Rg1 [10] (Fig. 1) was proven to improve synaptic transmission and increase the amplitude of long-term potentiation [54, 55]. It was revealed that ginsenosides Rg1 and Rb1 [11] (Fig. 1) enhanced central nervous system (CNS) cholinergic metabolism. They were found to potentiate the cholinergic system by (1) increasing the density of central M-cholinergic receptors and (2) enhancing the level of ACh in the CNS (through increasing acetyltransferase activity or inhibiting AChE activity) [56, 57]. Korean red ginseng saponins with a low PD/PT (protopanaxadiol/protopanaxatriol) ratio have been shown to improve spatial working memory whereas those with a high PD/PT ratio do not [45]. Ginsenoside Rg1, panaxatriol with two sugars, is generally more nootropic than Rb1, panaxadiol with four sugars. Increased protein biosynthesis as evidenced in the mouse brain may contribute to the memory consolidative effect conferred by ginsenosides Rb1 and Rg1 [58].

**Polygala tenuifolia** Willd. (Polygalaceae): It has been used for treatment of amnesia, neurasthenia, palpitation, nocturnal emission and insomnia. Either a methanolic extract or an acylated ollgosaccharide-containing fraction ameliorated the scopolamine-induced decrease of retention in passive avoidance by enhancing the central cholinergic system [59].

**Pueraria lobata** (Willd.) Ohwi (Fabaceae): *Puerarin [12] (Fig. 1)*, isolated from *P. lobata*, has exhibited attenuation of mecamylamine-, p-chloroamphetamine- or dizocilpine-induced inhibitory avoidance performance deficits but not the scopolamine-induced one. The beneficial effect of puerarin might be attributed to the enhanced cholinergic activity via nicotinic but not muscarinic receptors as well as activated NMDA receptors and decreased serotonergic neuronal activity [60].

**Pueraria thumbergiana** (Siebold & Zucc.) Benth. (Fabaceae): Daidzein [13] (Fig. 1) isolated from methanolic extracts of *P. thumbergiana* reversed the scopolamine-induced amnesia in the Y-maze test. Daidzein ameliorates scopolamine induced amnesia by acting as a choline acetyltransferase activator for Ach biosynthesis [61]. With extensive purification effort, daidzein has been successfully identified as the ChAT activator and one of the active ingredients responsible for memory enhancement. As admitted by the investigator, the precise working mechanisms for daidzein conferred memory enhancement remains largely unclear. Since
only the cholinergic pathway was studied, it remains unknown whether daidzein conferred protection through a single direct action at the cholinergic system or a combative effect occurring at multiple action sites.

**Salvia miltiorrhiza Bge. (Labiatae):** Tanshinones are a group of diterpenoids isolated from the roots of *S. miltiorrhiza*. Tanshinone I (14), tanshinone IIA (15), cryptotanshinone (16), and 15, 16-dihydrotanshinone I (17) are collectively called tanshinone congeners. Tanshinone I, tanshinone II A, cryptotanshinone and 15,16-dihydrotanshinone I significantly reversed the cognitive impairment induced by scopolamine. Cryptotanshinone and 15,16-dihydrotanshinone I were proven to induce an inhibitory effect on AChE in *in vitro* and *ex vivo* studies. Tanshinone congeners may exert a beneficial effect on cognitive impairment by cholinergic signaling enhancement [62].

**Salvia triloba L.f. (Lamiaceae):** Its hydroalcoholic extract exerted a memory enhancing effect partially through AChE inhibition with an IC50 value of 0.71 mg/mL. Its hydroalcoholic extract exerted a memory enhancing effect partially through radical scavenging activity against 2,2-diphenylpicrylhydrazyl radical with an IC50 value of 0.227 mg/mL [63].

**Scrophularia buergeriana Miq. (Scrophulariaceae):** E-Harpagoside (18) and MCA-Hg (19) were isolated from *S. buergeriana*. E-Harpagoside, enhance cognition by inhibiting the activity of AChE within the cortex and hippocampus to a level similar to that observed in donepezil-treated rats/mice [64]. In another study, E-p-methoxy-cinnamic acid (E-p-MCA), a phenylpropanoid isolated from roots of *S. buergeriana*, improved impairments of spatial learning and memory induced by scopolamine [65]. Although the underlying mechanism is not yet fully elucidated, the α,β-unsaturated carbonyl moiety and the para-methoxy group in E-p-MCA are postulated to be crucial components in cognition-enhancing activity.

**Schizandra chinesis (Turcz.) Baill. (Schisandraceae):** Gomisin A (20) is a fruit of *S. chinesis*. Gomisin A reverses the cognitive impairment induced by scopolamine in the passive avoidance test, Y-maze test and Morris water maze test. The cognition-enhancing effect of gomisin A was partially exerted through inhibition of AChE activity dose-dependently [66].

**Teucrium polium L. (Lamiaceae):** Its hydroalcoholic extract exerted a memory enhancing effect partially through AChE inhibition with an IC50 value of 0.55 mg/mL [63].

**Thebesia populnea Mil. (Malvaceae):** It has been reported to have antifertility, antibacterial, anti-inflammatory, antioxidant, purgative and hepatoprotective activities. An ethanolic extract of *T. populnea* reversed the scopolamine-induced amnesia through reduced brain cholinesterase activity [67].

**Tremella fuciformis Berk. (Tremellaceae):** It has been demonstrated that *T. fuciformis* extract reduced scopolamine-induced learning and memory deficits by increasing the central cholinergic activity in the medial septum and hippocampus. In consistency with an animal study, the water extract of *T. fuciformis* promoted neurite outgrowth of PC12h cells. These findings have demonstrated that the anti-amnesic effect of *T. fuciformis* was conferred partly through the cholinergic system and promotion of neurogenesis. Neurogenesis has been demonstrated to play a crucial role in regulating memory and learning; it would be helpful if the active ingredients responsible for the protection could be identified and further studied [68].

**Uncariae ramulus et Uncus. (Rubiaceae):** Its methanolic extract induced significant reversals of ibotenic acid-induced deficit in learning and memory by reducing the loss of cholinergic immunoreactivity in the hippocampus [69].

**Action through GABAergic nervous system**

Several studies have indicated the importance of GABAergic involvement in memory formation. Drugs enhancing GABA_A and GABA_B neurotransmission cause memory impairment whereas drugs reducing GABA_A neurotransmission lead to memory enhancement in rodents. Thus, modulation of GABAergic neurotransmission could possibly lead to advancements in treating amnesia.

**Bacopa monniera (L.) Penn. syn. (Scrophulariaceae):** *B. monniera* has been used for treating epilepsy, insomnia, anxiety and memory enhancement. Standardized extracts of *B. monniera* containing 55.35% bacosides have been shown to alleviate diazepam-induced amnesia as evidenced by decreased escape latency time. This protective effect may act through the GABA-benzodiazepine pathway possibly affecting long-term potentiation [70].

**Salvia miltiorrhiza Bge. (Labiatae):** Tanshinone I (14) and II A (15) were isolated from *S. miltiorrhiza*, restored the diazepam (a GABA_A/benzodiazepine receptor agonist) induced memory deficits in a passive avoidance test. This implied that tanshinone I or tanshinone II A prevented cholinergic dysfunction-related deterioration of learning and memory through the GABAergic neurotransmitter system [62].

**Scutellaria baicalensis Georgi. (Lamiaceae):** Oroxylin A (21) is a flavonoid, isolated from the root of *S. baicalensis*. Rats/mice pretreated with oroxylin A significantly reversed the scopolamine or diazepam-induced cognitive impairments as revealed in passive avoidance and Y-maze testing. In the Morris water maze, the escape latencies in training trials were improved and the swimming times and distances within the target zone increased in oroxylin A treated amnesic rats/mice. The ameliorating effect of oroxylin A was reversed by the GABA_A receptor agonists (either muscimol or diazepam). In addition, oroxylin A inhibited the GABA-induced inward chloride ion current in a single cortical neuron. It was suggested that oroxylin A protected against scopolamine-induced memory impairment via the GABAergic nervous system [71].

**Action through glutamatergic nervous system**

Glutamate synapse is a potential target for drug intervention in amnesia. Two glutamatergic therapeutic approaches are AMPA and NMDA poteniations. Compounds like AMPAkines (potentiating glutamate’s action at AMPA receptors) and D-cycloserine (a partial agonist at the glycine site of NMDA receptor) have demonstrated memory enhancement effects [72, 73]. Glutamate receptors have been reported to play a pivotal role in learning and memory. Blockade of NMDA receptors with selective inhibitors abolishes long-term potentiation (LTP) in the CA1 region of the hippocampus and also blocks spatial learning [74]. It is suggestive that NMDA receptors are involved in the learning process.

**Ginkgo biloba L. (Ginkgoaceae):** Chronic administration of *G. biloba* has been shown to remove memory disturbance induced by MK-801, which is a N-methyl-D-aspartate acid (NMDA) receptor blocker. Ginkgo improved memory retention by enhancing the glutamatergic system partially [75].

**Panax ginseng C.A. Meyer (Araliaceae):** Ginsenosides Rg3(R), Rg3(S) or Rg5/Rk1 (a mixture of Rg5 and Rk1, 1:1. w/w) significantly ameliorated ethanol-induced memory impairment. In addition, ginsenosides Rs3(S) and Rg5/Rk1 significantly alleviated scopolamine-induced memory impairment. Collectively, neuroprotective actions of these three ginsenosides against memory impairment may be partly attributed to their anti-excitotoxic (glutamate or N-methyl-D-aspartate) abilities [76]. Ginseng has
long been used as a tonic remedy and is one of the most widely used medicinal plants for memory enhancement or anti-aging. The memory enhancing effects of two representative constituents in ginseng, ginsenoside Rb1 and Rg1 have been widely studied while the roles of other ginsenosides in anti-amnesia were unclear. To the best of our knowledge, that was the first research paper published in English demonstrating the memory enhancing effects of ginsenosides Rg3(S) and Rg5/Rk1.

**Uncariae rhynchophylla (Miq.) Jacks. (Rubiaceae):** Its methanolic extract or alkaloid fraction has been shown to reduce ethanol-induced amnesia by recovering an ethanol-induced decrease in glutamic acid level [77].

### Action through serotonergic nervous system

Serotonin (5-HT) has a dual role in the cognitive process that can either strengthen or suppress memory depending on the timing of memory formation. Among the different subtypes of 5HT receptors, 5-HT1A, 5-HT4, 5-HT6 and/or 5-HT7 receptors play prominent roles in memory formation. The 5-HT3 receptor antagonism approach has been proposed for treatment of amnesia. Release of ACh in the cortex was inhibitorily controlled by the 5-HT3 receptor [78].

**Schisandra chinensis** (Turcz.) Baill. (Tremellaceae): The water layer of fruit of *S. chinensis* counteracted the cycloheximide-induced amnesia. The ameliorating effect was amplified by treatment with a serotonergic 5-HT2 receptor antagonist (ritanserin) but reduced by treatment with a serotonergic 5-HT1A receptor agonist (8-OD-PAT) as well as GABAa (bicuculline) and cholinergic receptor agonists (scopolamine) [79].

**Gastrodia elata** Bl. (Orchidaceae): p-Hydroxybenzyl alcohol (HBA) [22] (Fig. 1) is an aglycone of gastrodin and active ingredient of *G. elata*. Results showed that HBA can attenuate scopolamine-induced amnesia by recovering an ethanol-induced decrease in glutamic acid level [77].

### Action through other nervous systems

**Ginkgo biloba** L. (Ginkgoaceae): Standardized GBE was reported to antagonize scopolamine-induced spatial memory deficit [84]. It was found to inhibit a diphenhydramine- (potent anticholinergic agent)-induced or pyrilamine (H1 receptor antagonist)-induced increase in the total error, reference working error and working memory error. These findings concluded that standardized GBE confers protection partially through cholinergic and histaminergic mechanisms. Histamine has been reported to play an important role in learning and memory via H1 receptors [85, 86].

**Panax ginseng** C. A. Mey. (Araliaceae): Ethanol-induced acquisition impairment was significantly reduced by single or repeated administration of red ginseng total saponins (RGTS). The inhibitory effect of RGTS on ethanol-induced amnesia was abolished by pretreatment of alpha-methyl-p-tyrosine (inhibitor of catecholamine synthesis) in a dose-response manner but not by p-chlorophenylalanine (inhibitor of serotonin synthesis). RGTS confer anti-amnesic effects through catecholaminergic rather than serotonergic neuronal activity [87].

### Three Herbs Showing Promising Memory Enhancing Capabilities

Extensive basic research studies on amnesia have been conducted over the past few decades with the attempt to investigate the anti-amnesic therapeutic potentials of various herbs. Although a number of herbal medicines have been demonstrated with anti-amnesic effects, clinical trials on the use of herbal medicines for the treatment of amnesia have not yet been published. Despite the difficulty of new drug development, several research groups have discovered some herbs with promising efficacies in the clinical setting and great application potential in memory enhancement in healthy subjects, patients with dementia or AD which could be potential candidates for amnesia as well. Clinical data regarding trials of *Centella asiatica*, *C. biloba* and *H. serrata* in human beings are summarized below.

**Centella asiatica** (L.) Urb., (Apiaceae)

The cognitive-enhancing effect of *C. asiatica* (250, 500 and 750 mg once daily for 2 months) was tested in 28 healthy elderly subjects in a randomized, placebo-controlled, double-blind study. Treatment with a high dose (750 mg) of *C. asiatica* repeatedly for two months increased the percentage accuracy of both numeric working memory and word recognition, the reaction time of both numeric working memory and spatial memory as well as the N100 component amplitude of event-related potential [88].

**Ginkgo biloba** L. (Ginkgoaceae)

In a randomized, double-blind, placebo-controlled trial, healthy volunteered participants were randomly divided into two groups: Ginkgo (40 mg, thrice/day) and matching placebo for 6 weeks. There was no significant difference in standard neuropsychological tests of learning, memory, attention and concentration or naming and verbal fluency between the ginkgo and placebo groups [89]. In another randomized, double-blind, placebo-controlled clinical trial, 3069 volunteers were assessed every 6 months for incident dementia with a median follow-up of 6.1 years. The overall dementia rate was 3.3 per 100 person years in Ginkgo group versus 2.9 per 100 person years in placebo group.
was concluded that G. biloba at 120 mg twice a day did not reduce the occurrence of dementia or AD in elderly people with normal cognition or with mild cognitive impairment [90].

**Huperzia serrata** (Thunb.) Trev. (Lycopodiaceae)

Huperzine A, derived from *H. serrata*, has been shown to have antioxidant and neuroprotective properties. The neuroprotective effects of huperzine A have been widely studied in AD patients especially in China. It has been suggested that this herb may be as effective as tacrine and donepezil in the symptomatic treatment of dementia. Clinical efficacy and safety of huperzine A has been demonstrated in AD patients in different randomized and placebo-controlled trials in China. In an earlier study, fifty AD patients were administered with either huperzine A or placebo for eight weeks. Improvement in memory, cognition and behavioral functions was shown in 58% of the huperzine A-treated group and only 36% of the placebo group [91]. In another larger scale clinical study, 202 patients aged between 50 and 80 were divided into two groups: Huperzine A (n = 100, 100 µg twice for week 1; 150 µg twice for week 2–3; 200 µg twice for week 4–12) or placebo for 12 weeks. Improvement in terms of cognition, behavior, mood and activity of daily life was found in 70% of the huperzine A-treated groups but only 36% of the placebo group [92]. Another study has also demonstrated that huperzine A is 8-fold more potent than donepezil and 2-fold more potent than rivastigmine in increasing cortical Acch levels and has a longer lasting effect [93].

**Difficulties Hindering Transition to Clinical Studies ▼**

One of the obstacles hindering the transition of basic animal research to human clinical research may be attributed to the dispersed and unsystematic basic experimental design. Most of the studies included a sham or placebo control, but not a positive control. It would have been valuable to compare the efficacy of these herbal medicines with the commonly used FDA-approved AChE inhibitors like tacrine (available since 1993), donepezil (available since 1996), rivastigmine (available since 2000) and galantamine (approved in 2001). Besides, most of the aforementioned animal studies only examine one mechanism of the anti-amnesic effect while the lack of follow-up studies on other relevant pathways prevents further progress on understanding the comprehensive effect of these herbs on amnesia. The anti-amnesic effect of herbal medicine may stem from protective actions on the cholinergic, GABAergic, glutamatergic, serotonergic, catecholaminergic and histaminergic nervous systems. Protective actions on the dopaminergic system cannot be neglected as dopaminergic agents have been reported to ameliorate anoxia-induced memory impairments and enhance learning in healthy adults [94,95]. The cAMP-PKA signaling pathway has been suggested to modulate dopaminergic neurotransmission of synaptic plasticity in memory consolidation [96,97]. However, the mechanisms of the regulation of synaptic plasticity by neurotransmitters and intracellular signal transduction are not yet fully elucidated. Given the scant information on the underlying anti-amnesic mechanisms, how these herbal medicines confer protection will definitely require further investigation and elucidation.

In new drug development, data obtained from animal studies provide a framework for further clinical trials. Appropriate translation of drug dose across species would definitely have a great impact on the overall effectiveness. By the conventional translation method, animal dose multiplied by human body weight (60 kg) equal to human equivalent dose, could cause serious misinterpretation and inapplicability of the research [98]. Instead, another calculation, the body surface area (BSA) normalization method which considers several parameters like oxygen utilization, caloric expenditure, basal metabolism, blood volume, circulatory plasma proteins and renal functions could provide a more appropriate conversion of drug doses from animal studies to human trials [99]. The formula for dose translation based on BSA is as follow:

\[
\text{Human equivalent dose (mg/kg)} = \frac{\text{Animal dose (mg/kg)}}{\left(\frac{\text{Animal Km}}{\text{Human Km}}\right)}
\]

where Km factor is equal to body weight (kg)/BSA(m²).

However, BSA dosing does not take the complex process of drug elimination into consideration therefore overdosing and underdosing could occur affecting the overall therapeutic effects. Further research effort is still needed to formulate a better dose translation method across different species.

**Characteristics of Herbs Suitable for Treating Amnesia ▼**

There are three critical criteria for selecting herbal drugs for the treatment of amnesia, including (1) high bioavailability, (2) ability to cross the BBB and (3) minimal adverse and toxic effects. Bioavailability is defined as the “absorption and utilization of a nutrient” [100]. Upon oral consumption, a herbal extract is expected to cross the intestinal barrier and enter the systemic circulation. The bioavailability of herbs can vary considerably from different plant types and from person-to-person. Based on the studies from Manach et al., and Williamson and Manach in 2005 [101,102], the bioavailability of different types of flavonoids is as follows (from most to least bioavailable): isoflavonoids, gallic acid > catechins, flavones, quercetin glucosides > proanthocyanidins, galloylated tea catechins, anthocyanins. Future research on pharmacokinetics and pharmacodynamics studies of other bioactive components could be beneficial to new drug development. For any drugs to be effectively functional in the CNS, they must first penetrate through the BBB. Numerous efflux transporters are expressed on the surface of BBB, such as P-glycoprotein, multi-drug resistance associated protein and monocarboxylic acid transporters. Flavonoids interact with one or several of these transporters either directly or indirectly through stimulatory or inhibitory modes [103]. Two bioactives in Ginkgo, quercetin and kaempferol stimulate P-glycoprotein transporters whereas sertralol in grape seeds inhibit P-glycoprotein transporters. The bioavailability of herbal drugs for the treatment of amnesia depends greatly on the extent to which they can cross the BBB.

While most of the available literature has been concentrated on studying efficacies of various herbs, information concerning the toxicological studies of herbal treatments on amnesia has been scanty so far. There were neither reports of any serious adverse nor toxic effects for the aforementioned herbs. To ensure the safe uses of these plant extracts or their bioactive components, acute and chronic toxicity tests in animals would be helpful to identify any potential hazards for human consumption although the aforementioned herbs do not classify as toxic herbs with reference to the Pharmacopoeia of People’s Republic of China. Besides, dosages of herbal medicines, like other Western pharmacueticals, play an important role in the overall pharmacological and toxic effect.
effects. In developing therapeutic strategies for treating amnesia, further investigation on bioavailability, BBB penetration and toxic/adverse effects would be invaluable.

**Current Issues and Future Perspectives**

Administration of medication to regulate the neurotransmitters is one of the methods for the treatment of amnesia. Currently, the use of AChE inhibitors to treat amnesia is still the mainstream pharmacotherapy. Although cholinesterase inhibitors – donepezil, galantamine, rivastigmine and tacrine are the four approved pharmacological therapies for dementia by the U.S. Food and Drug Administration, Raina et al. indicated that cholinesterase inhibitors only resulted in marginal clinical improvement as measured by cognition and global assessments [104].

**Rapid screening techniques**

Numerous activities of different active ingredients in herbs may be relevant to the treatment of cognitive disorders while the complicated pathophysiology of amnesia has not been fully elucidated. With special attention paid to the enhancement of cholinergic neurotransmission, the majority of research has been focused on anti-cholinesterase alkaloids. However, other pharmacological targets are also of great importance. Given a diverse array of compounds from thousands of herbs, a rapid screening method would be useful to delineate the scope of potential compounds for in-depth investigation. cDNA microarray technology which simultaneously monitors several pathways could possibly accelerate the elucidation of the underlying mechanisms of potential herbal medicines and provide solid evidence for further clinical investigation. With this new methodology, the overall cellular changes and wide spectrum of differentially expressed genes upon chemical-induced amnesia can be revealed. Alternative novel pathways such as apoptosis, cytoskeleton reconstruction, protein trafficking and cell differentiation can be closely monitored in addition to targeting muscarinic ACh receptors and their associated signaling molecules [105]. Recently, using the microarray and quantitative real-time RT-PCR approaches, Homer1, GABA(B) receptor, early growth response 1, prodynorphin, VGF nerve growth factor inducible and several novel genes including calcium/calmodulin-dependent protein kinase 2 and glycophorin C were revealed following scopolamine treatment [106]. The above proteins and RNAs could be targeted and modulated by the administration of herbal medicines that may have beneficial effects on amnesia.

Genetically knockout mice models

As the pathophysiology of amnesia is complicated where different mechanistic pathways are interrelated, the uses of genetic knockout mice models which are deficient in particular receptors of neurotransmitters or specific antioxidant relevant genes may help to delineate protective effects of herbs or active therapeutical components. Most of the aforementioned reports are unable to conclude whether the observed improvement was due to a single direct action of the drug at, for example, the cholinergic system, or the combinative actions at several different sites. Employing genetically knockout mice to study anti-amnestic effects of potential herbs will give a clearer picture of at least some of the underlying mechanisms.

**Synthetic single compound with multiple target actions**

A herbal medicine, which shows favorable effects on cognitive disorders as evident in a wide variety of experimental studies, has a great potential for clinical use. Active ingredients in herbal medicine can act synergistically with other ingredients as well as counterbalance toxic effects of other active components. In 2007, Decker proposed the idea of hybrid molecules in which a single molecule has multiple pharmacological actions [107]. Administration of a single compound is expected to result in more predictable pharmacokinetics and pharmacodynamics as well as improved compliance in patients. One part of the hybrid molecule can have AChE inhibitory activity whereas another part can target GABAergic, glutaminergic, histaminergic, serotonergic and catecholaminergic systems. Achieving an optimal balance of the therapeutic activities of the different parts of the hybrid molecules is more important than obtaining the maximal activity of a single part. The degree of recovery and the duration of treatment period using herbal medicine are expected to vary with the location and severity of the lesioned brain areas as well as the type of amnesia. Different types of herbs may also be beneficial for different damaged brain areas or types of amnesia. Further in-depth research would be valuable to all amnestic patients.

**Conclusion**

Many herbs have been preliminarily demonstrated to pose protective effects against amnesia in animal models. Natural products not only demonstrate specific effects on particular pathways, but also act synergistically on the neural systems with other components. However, limited studies on the mechanism, pharmacology and toxicology of these herbal medicines are available, which seriously hinder their development for clinical uses. It will further be of value to elucidate the structural features and bioactivities of herbal drugs that are relevant to their neuroprotective properties. In addition to current cholinergic-based strategies, other approaches involving GABAergic, glutaminergic, catecholaminergic, histaminergic, serotonergic and dopaminergic systems are also critical to rationalize drug development for the treatment of amnesia, dementia and other related neurological complications.

**References**


This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
56 Zhang J, Liu L, Qu SM, Zhang XL, Xiao HL. Influence of ginsenoside Rb1 and Rg1 on some central neurotransmitter receptors and protein bio-synthesis in the mouse brain. Yao Xue Xue Bao 1988; 23: 12–16
61 Orhan I, Aslan M. Pharmacal study of Scutellaria baicalensis in scopolamine-treated mice. Eur J Pharmacol 2008; 578: 78–84
64 Tsudaev M, M. Pharmacological and Toxicological Actions of Thespesia populnea relevant to Alzheimer’s disease. Phytomedicene 2006; 13: 135–139
75 Tsudaev M, M. Pharmacological and Toxicological Actions of Thespesia populnea relevant to Alzheimer’s disease. Phytomedicene 2006; 13: 135–139